triflusal has been researched along with Disease Models, Animal in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amtul, Z; Cechetto, DF; Haque, W | 1 |
| Arumugam, S; Boey, FY; Huang, Y; Mohanty, M; Umashankar, PR; Venkatraman, SS | 1 |
| Agulló, J; Bacskai, BJ; Borrelli, LA; Clarimón, J; Coma, M; Da Rocha-Souto, B; España, J; Garcia-Alloza, M; Gómez-Isla, T; Guardia-Laguarta, C; Hyman, BT; Lleó, A; Rodríguez, M; Sánchez, MB; Saura, CA; Scotton, TC; Serenó, L | 1 |
| Frautschy, SA | 1 |
| Balduini, W; Cechetto, DF; Cheng, G; Cimino, M; Hachinski, VC; Massoni, E; Whitehead, SN | 1 |
| Acarin, L; Castellano, B; González, B | 1 |
| Arrebola, MM; De La Cruz, JP; González-Correa, JA; Guerrero, A; Muñoz-Marín, J; Ruiz-Villafranca, D; Sánchez De La Cuesta, F; Ureña, IM | 1 |
| Cechetto, DF; Cheng, G; Hachinski, V; Whitehead, S | 1 |
| Allen, GV; Bayona, NA; Cechetto, DF; Cheng, G; Hachinski, VC; Whitehead, SN | 1 |
| Badimon, L; Duran, X; Sánchez, S; Vilahur, G | 1 |
| Bellés, L; Forn, J; García Rafanell, J | 1 |
11 other study(ies) available for triflusal and Disease Models, Animal
| Article | Year |
|---|---|
Dipyridamole plus Triflusal versus Triflusal Alone in Infarct Reduction after Middle Cerebral Artery Occlusion.
Topics: Animals; Brain; Cytoprotection; Dipyridamole; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Infarction, Middle Cerebral Artery; Male; Neuroprotective Agents; Rats, Wistar; Salicylates | 2018 |
The short-term effect on restenosis and thrombosis of a cobalt-chromium stent eluting two drugs in a porcine coronary artery model.
Topics: Animals; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Chromium Alloys; Coronary Restenosis; Coronary Vessels; Disease Models, Animal; Drug Therapy, Combination; Drug-Eluting Stents; Immunosuppressive Agents; Platelet Aggregation Inhibitors; Prosthesis Design; Salicylates; Sirolimus; Swine; Thrombosis; Treatment Outcome | 2009 |
Triflusal reduces dense-core plaque load, associated axonal alterations and inflammatory changes, and rescues cognition in a transgenic mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Axons; Brain; Brain-Derived Neurotrophic Factor; Central Nervous System Agents; Cognition Disorders; Cytokines; Disease Models, Animal; Humans; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neuroglia; Plaque, Amyloid; Proto-Oncogene Proteins c-fos; Salicylates | 2010 |
Thinking outside the box about COX-1 in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Central Nervous System Agents; Cognition Disorders; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Humans; Membrane Proteins; Mice; Salicylates | 2010 |
Triflusal reduces cerebral ischemia induced inflammation in a combined mouse model of Alzheimer's disease and stroke.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Antigens, CD; Brain Ischemia; Disease Models, Animal; Endothelin-1; Humans; Inflammation; Mice; Mice, Inbred C57BL; Mice, Transgenic; NF-kappa B; Platelet Aggregation Inhibitors; Salicylates; Stroke; tau Proteins; Tumor Necrosis Factor-alpha | 2010 |
Decrease of proinflammatory molecules correlates with neuroprotective effect of the fluorinated salicylate triflusal after postnatal excitotoxic damage.
Topics: Administration, Oral; Animals; Astrocytes; Cyclooxygenase 2; Disease Models, Animal; Inflammation Mediators; Interleukin-1; Isoenzymes; Microglia; Microinjections; N-Methylaspartate; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Neurotoxins; Neutrophil Infiltration; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Long-Evans; Salicylates; Somatosensory Cortex; Tumor Necrosis Factor-alpha | 2002 |
Effects of triflusal on oxidative stress, prostaglandin production and nitric oxide pathway in a model of anoxia-reoxygenation in rat brain slices.
Topics: Analysis of Variance; Animals; Aspirin; Disease Models, Animal; Dose-Response Relationship, Drug; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Glutathione Transferase; Hypoxia; In Vitro Techniques; L-Lactate Dehydrogenase; Lipid Peroxidation; Male; Nitrates; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Oxidative Stress; Oxygen; Platelet Aggregation Inhibitors; Prostaglandins; Rats; Rats, Wistar; Salicylates | 2004 |
Interaction between a rat model of cerebral ischemia and beta-amyloid toxicity: II. Effects of triflusal.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Astrocytes; Behavior, Animal; Brain; Brain Ischemia; Corpus Striatum; Cytokines; Disease Models, Animal; Endothelins; Glial Fibrillary Acidic Protein; Hippocampus; Immunohistochemistry; Inflammation; Microglia; Neurons; Peptides; Rats; Rats, Wistar; Salicylates; Temperature | 2005 |
Effects of triflusal and aspirin in a rat model of cerebral ischemia.
Topics: Animals; Aspirin; Brain Ischemia; Disease Models, Animal; Drug Therapy, Combination; Male; Rats; Rats, Wistar; Salicylates | 2007 |
Protective effects of triflusal on secondary thrombus growth and vascular cyclooxygenase-2.
Topics: Animals; Aspirin; Base Sequence; Blood Vessels; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Disease Models, Animal; DNA Primers; Endothelium, Vascular; Fibrinolytic Agents; In Vitro Techniques; Male; Perfusion; Rabbits; Recurrence; RNA, Messenger; Salicylates; Thrombosis | 2008 |
[Induction of pulmonary thrombosis in mice, rabbits and hamsters by intravenous injection of arachidonic acid. Comparative study of 3 experimental models in vivo and the antithrombotic activity of triflusal].
Topics: Animals; Arachidonic Acids; Cricetinae; Disease Models, Animal; Fibrinolytic Agents; Injections, Intravenous; Lung Diseases; Mice; Rabbits; Respiration Disorders; Salicylates; Thrombosis | 1979 |